転移性肝がん(Metastatic Liver Cancer)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Metastatic Liver Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Metastatic Liver Cancer – Overview 7
Pipeline Products for Metastatic Liver Cancer – Comparative Analysis 8
Metastatic Liver Cancer – Therapeutics under Development by Companies 9
Metastatic Liver Cancer – Therapeutics under Investigation by Universities/Institutes 10
Metastatic Liver Cancer – Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Metastatic Liver Cancer – Products under Development by Companies 13
Metastatic Liver Cancer – Products under Investigation by Universities/Institutes 14
Metastatic Liver Cancer – Companies Involved in Therapeutics Development 15
AB Science 15
Arrowhead Research Corporation 16
Mirna Therapeutics, Inc. 17
Provectus Biopharmaceuticals, Inc. 18
Transgene Biotek Limited 19
Metastatic Liver Cancer – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
masitinib – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Monoclonal Antibody Conjugate to Target CEA for Metastatic Liver, Colorectal Cancer and Solid Tumor – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
MRX-34 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Oncolytic Virus for Liver Metastases and Primary Liver Tumors – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Peptide to Inhibit Hemofiltrate CC Chemokine for Metastatic Liver Cancer – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
PSL–001 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
PV-10 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Stem Cell Therapy for Oncology – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
TBL-0404 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Metastatic Liver Cancer – Recent Pipeline Updates 43
Metastatic Liver Cancer – Dormant Projects 61
Metastatic Liver Cancer – Discontinued Products 62
Metastatic Liver Cancer – Product Development Milestones 63
Featured News & Press Releases 63
Mar 06, 2014: PV-10 Immune Mechanism Data to Be Presented at the American Association for Cancer Research Annual Meeting 63
Jan 14, 2014: Mirna Therapeutics Reports Expansion of Intellectual Property Estate 64
Oct 24, 2013: Provectus Awarded PV-10 Patent by U.S. Patent and Trademark Office 64
Sep 27, 2012: Provectus Pharma Expands Protocol For Phase I Liver Cancer Study 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67